Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 2.
doi: 10.1007/s13402-025-01086-1. Online ahead of print.

Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential

Yaqian Han #  1 , Shizhen Li #  1 , Linda Oyang #  1 , Shiwen Cui  1 , Wenlong Zhang  1 , Wenjuan Yang  1 , Mingjing Peng  1 , Shiming Tan  1 , Longzheng Xia  1 , Jinguan Lin  1 , Xuemeng Xu  1 , Nayiyuan Wu  1 , Xianjie Jiang  1 , Qiu Peng  1 , Yanyan Tang  1 , Xia Luo  1 , Qianjin Liao  2   3 , Yujuan Zhou  4   5
Affiliations
Review

Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential

Yaqian Han et al. Cell Oncol (Dordr). .

Abstract

Abnormal post-translational modifications (PTMs) play a crucial role in tumor initiation and progression. However, the mechanisms by which lncRNAs, as emerging epigenetic regulators, mediate PTMs remain largely unexplored. This review provides a comprehensive summary of the latest research on the interplay between lncRNA-mediated PTMs and tumorigenesis. We delve into the molecular mechanisms underlying these interactions, focusing on how lncRNAs regulate PTMs to influence tumor progression. We place particular emphasis on the lncRNA-mediated PTMs as a driver of therapeutic resistance, shedding light on its potential as a novel target for cancer intervention. Furthermore, we highlight the therapeutic potential of targeting lncRNA-PTM networks, emphasizing novel RNA-based strategies and their clinical relevance in cancer treatment. We believe that an in-depth understanding of lncRNA-mediated PTMs could uncover novel therapeutic targets, paving the way for innovative approaches in cancer diagnosis and treatment.

Keywords: Cancer; PTMs; Therapeutic tolerance; lncRNAs; ncRNAs.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Q. Zhong et al., Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications. MedComm (2020). 4, e261 (2023) - PubMed - DOI
    1. X. Wu et al., Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Signal. Transduct. Target. Ther. 8, 220 (2023) - PubMed - PMC - DOI
    1. K. Tunyasuvunakool et al., Highly accurate protein structure prediction for the human proteome. Nature. 596, 590–596 (2021) - PubMed - PMC - DOI
    1. D. Hanahan, Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022) - PubMed - DOI
    1. Y. Xue et al., Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo. Proc. Natl. Acad. Sci. U S A 120, e2219978120 (2023) - PubMed - PMC - DOI

LinkOut - more resources